Drug Landscape ›
Bacillus coagulans ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 121
Most-reported reactions
Nausea — 19 reports (15.7%) Fatigue — 16 reports (13.22%) Pain — 14 reports (11.57%) Blood Pressure Increased — 11 reports (9.09%) Diarrhoea — 11 reports (9.09%) Headache — 11 reports (9.09%) Condition Aggravated — 10 reports (8.26%) Drug Ineffective — 10 reports (8.26%) Pneumonia — 10 reports (8.26%) Dizziness — 9 reports (7.44%)
Source database →
Bacillus coagulans in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Bacillus coagulans approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Bacillus coagulans in United States?
Xijing Hospital of Digestive Diseases is the originator. The local marketing authorisation holder may differ — check the official source linked above.